- EUR 175 million invested in new facilities in Austria and Germany
- EUR 150 million allocated to penicillin production in Kundl, Austria
- EUR 25 million for biosimilar development center in Holzkirchen, Germany
- Austrian federal and Bavarian state governments support the projects
Investment and Facilities
Sandoz has invested EUR 175 million to open two new facilities in Europe: an antibiotic production plant in Kundl, Austria, and a biosimilar development center in Holzkirchen, Germany. This investment includes EUR 150 million for the penicillin production plant, with EUR 50 million contributed by the Austrian federal government, and EUR 25 million for the biosimilar center.
Penicillin Production
The new facility in Kundl will enhance the production of penicillin, the leading category of antibiotics worldwide. Sandoz maintains the only major vertically-integrated production network for penicillins in Europe. The upgraded plant aims to improve the ecological footprint and secure a stable European-based supply of penicillin API (active pharmaceutical ingredient).
Biosimilar Development
The Holzkirchen center will focus on the development of biosimilars, becoming a global hub for analytical characterization. This cutting-edge facility is expected to support the long-term growth of Sandoz's biosimilar business, reinforcing its position in the market.
Government Support
The Austrian federal and Bavarian state governments have shown strong support for these projects, recognizing their importance in ensuring the availability of critical medicines and advancing medical research in Europe.
